Zacks Small Cap Lifts Earnings Estimates for Cytosorbents

Key Points

• Zacks Small Cap has increased its FY2025 earnings per share estimate for Cytosorbents Corporation to ($0.20), improving from a prior estimate of ($0.21).
• Cytosorbents reported quarterly earnings of ($0.05) per share, surpassing analysts' expectations of ($0.07), but fell short on revenue with $9.62 million against a forecast of $9.79 million.
• Institutional investors now own 32.87% of Cytosorbents' stock, with several hedge funds recently increasing their holdings in the company.

Cytosorbents Corporation (NASDAQ:CTSO - Free Report) - Stock analysts at Zacks Small Cap upped their FY2025 earnings estimates for shares of Cytosorbents in a note issued to investors on Wednesday, August 13th. Zacks Small Cap analyst T. Kerr now anticipates that the medical research company will post earnings of ($0.20) per share for the year, up from their prior forecast of ($0.21). The consensus estimate for Cytosorbents' current full-year earnings is ($0.30) per share.

A number of other analysts also recently commented on the stock. Wall Street Zen began coverage on shares of Cytosorbents in a report on Wednesday, May 21st. They issued a "hold" rating on the stock. D. Boral Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a report on Wednesday. Finally, HC Wainwright reiterated a "neutral" rating and issued a $1.00 target price on shares of Cytosorbents in a report on Thursday, May 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $5.50.

Cytosorbents Price Performance

Shares of NASDAQ CTSO traded up $0.0691 during midday trading on Monday, reaching $0.9131. The company's stock had a trading volume of 349,614 shares, compared to its average volume of 369,540. The company has a current ratio of 2.34, a quick ratio of 1.96 and a debt-to-equity ratio of 1.24. The company has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.03. Cytosorbents has a one year low of $0.7101 and a one year high of $1.61. The company has a market cap of $57.31 million, a price-to-earnings ratio of -5.37 and a beta of 1.19.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. The business had revenue of $9.62 million for the quarter, compared to the consensus estimate of $9.79 million.

Hedge Funds Weigh In On Cytosorbents

A number of large investors have recently made changes to their positions in the business. Avenir Corp increased its holdings in shares of Cytosorbents by 0.3% in the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company's stock valued at $6,475,000 after purchasing an additional 13,619 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after purchasing an additional 37,519 shares during the period. CM Management LLC increased its holdings in shares of Cytosorbents by 36.3% in the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock valued at $954,000 after purchasing an additional 254,076 shares during the period. Skylands Capital LLC increased its holdings in shares of Cytosorbents by 7.9% in the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock valued at $3,003,000 after purchasing an additional 221,080 shares during the period. Finally, Key Client Fiduciary Advisors LLC increased its holdings in shares of Cytosorbents by 127.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock valued at $78,000 after purchasing an additional 43,900 shares during the period. Institutional investors and hedge funds own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.